Trust Score calculated by AI analyzing study rigor, sample size (n), and the scientific source impact factor.
Intravenous mitochondria‑rich cytochalasomes cut infarct size by 52% in mouse heart ischemia/reperfusion
Summary
“A single IV injection of mitochondria‑rich cytochalasomes reduced myocardial infarct size by 52% and preserved cardiac function for up to 28 days in a murine I/R model.”
Adrian Castro created Biohacker Age to have a place to closely follow longevity and biological optimization research without relying on sensationalist headlines. Content is produced with AI assistance from scientific literature and is editorially reviewed before publishing.
About our methodology →The Finding
Gao and colleagues from the Department of Cardiology demonstrated that a single intravenous injection of mitochondria‑rich cytochalasomes (MRCs) cut myocardial infarct size by 52% in a murine ischemia/reperfusion (I/R) model.
How They Got There
The team conducted a controlled animal experiment using adult mice subjected to coronary artery occlusion followed by reperfusion. Subjects received either MRCs, isolated mitochondria, or vehicle control via tail‑vein injection.
| Variable | Measurement Method | Intervention Groups |
|---|---|---|
| Infarct size | Triphenyltetrazolium chloride (TTC) staining, planimetric analysis | MRCs vs. isolated mitochondria vs. vehicle |
| Macrophage phagocytosis of vesicles | Flow cytometry of peripheral blood mononuclear cells | MRCs vs. isolated mitochondria |
| Cardiac function | Echocardiography (ejection fraction, fractional shortening) | MRCs vs. controls, assessed up to 28 days |
Sample size was not disclosed in the abstract, but the experimental design included parallel groups for each treatment condition.
The Mechanism: What Happens Biologically
MRCs are generated by remodeling the cytoskeleton of mesenchymal stem cells, which traps functional mitochondria inside vesicles enriched with immunomodulatory proteins. After intravenous delivery, the vesicles avoid rapid macrophage clearance—phagocytosis drops by more than sixfold—because surface proteins signal “self.” Rather than fusing with host mitochondria, MRCs are routed to lysosomes, where they provoke a protective autophagy‑lysosomal response. This non‑fusogenic pathway preserves cellular energy balance without triggering deleterious mitochondrial integration.
Study Limitations
- Absence of a reported sample size hampers power assessment and reproducibility.
- Findings are confined to a single mouse strain; translational relevance to human cardiac physiology remains untested.
- Only one dose and a single administration were evaluated, leaving optimal dosing and repeat‑treatment effects unknown.
Practical Application
It is too early to translate this MRC platform into a personal performance or health protocol. Before actionable guidance can be offered, researchers must:
- Conduct dose‑response studies in larger animal cohorts to define safe and effective concentrations.
- Complete chronic toxicity and immunogenicity assessments over extended follow‑up periods.
- Validate efficacy in at least one phase‑I human trial, establishing pharmacokinetics, biodistribution, and preliminary cardiac outcomes.
Disclaimer: This article is for informational and educational purposes only. The information presented does not constitute medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before modifying your diet, supplementation, or exercise routines. The scientific studies cited reflect the state of knowledge at their publication date and may be subject to revision.
Legal Notice
Medical Disclaimer: This content is for informational and educational purposes only. It is not intended to substitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or supplementation.
Science in your inbox
The most relevant studies of the week, curated and analyzed.
No spam. Unsubscribe anytime.